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Background Concomitant structural degeneration of surgical mitral bioprostheses and paravalvular leak (PVL) is rare but potentially fatal.
Data pertaining to simultaneous transcatheter mitral valve implantation (TMVI) and percutaneous PVL closure are limited,
and the optimal treatment strategy remains undetermined. We report a case of simultaneous TMVI and double percutan-
eous PVL closure in a patient with a degenerated bioprosthetic mitral valve and associated medial and lateral PVLs.
...................................................................................................................................................................................................
Case summary A 75-year-old woman who underwent combined aortic (Edwards Perimount Magna 19mm) and mitral (Edwards
Perimount Magna 25mm) surgical valve replacement 6 years ago was referred for treatment of new-onset orthop-
noea and severely reduced exercise capacity. Transoesophageal echocardiography revealed severe mitral stenosis
and concomitant moderate to severe mitral regurgitation, originating from two PVLs located medial and lateral
from the surgical bioprosthesis. Due to high surgical risk, we performed successful transseptal mitral valve-in-valve
(ViV) implantation combined with the closure of two PVLs during the same procedure.
...................................................................................................................................................................................................
Discussion Although surgery should be considered as a first-line treatment in this setting, most patients have extremely high
or prohibitive surgical risk inherent to repeat open heart surgery. Mitral ViV implantation appears a reasonable
treatment option for patients with failed mitral bioprostheses. Furthermore, a recent study of percutaneous PVL
closure showed no significant difference in long-term all-cause mortality compared with redo open-heart surgery.
Simultaneous TMVI and percutaneous PVL closure appears feasible in selected high-risk patients.
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Learning points
• Simultaneous transcatheter mitral valve implantation (TMVI) and percutaneous paravalvular leak (PVL) closure can be an option in patients
with high surgical risk.
• Pre-procedural planning by multimodality imaging is crucial for a safe intervention when performing combined TMVI and percutaneous
PVL.
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Introduction
Concomitant surgical mitral bioprosthesis degeneration and dehis-
cence leading to paravalvular leak (PVL) is a rare but potentially fatal
condition. Although redo open-heart surgery is considered first-line
treatment, most patients are at prohibitive surgical risk, due to
advanced age and associated comorbidities. Recently, transcatheter
mitral valve-in-valve (ViV) implantation via the transseptal access has
been proposed as an alternative1–3 and may be combined with percu-
taneous PVL closure in selected patients.4 However, published data
are limited and optimal strategy remains to be determined.
We report a case of simultaneous transcatheter mitral valve im-
plantation (TMVI) and double percutaneous PVL closure in a patient
with degenerated bioprosthetic mitral valve and concomitant medial
and lateral PVL. Both step-by-step pre-procedural planning based on
multimodal imaging and procedural strategy are presented.
Timeline
Case presentation
A 75-year-old woman was referred for treatment of general fatigue,
new-onset orthopnoea, and severely reduced exercise capacity
(New York Heart Association functional Class III). She had under-
gone combined aortic (Edwards Perimount Magna 19mm) and mitral
(Edwards Perimount magna 25mm) surgical valve replacement
6 years ago.
Multimodality imaging—
transoesophageal echocardiography
Transoesophageal echocardiography (TOE) revealed severe mitral
stenosis with a mean transvalvular gradient of 16mmHg (Figure 1A;
Supplementary material online, Video S1). The mitral valve area was
0.5 cm2 measured by 3D TOE and 0.73 cm2 according to pressure
half time (PHT) (Supplementary material online, Video S2). In addition,
concomitant moderate to severe mitral regurgitation was found,
originating from two PVLs locatedmedial and lateral from the surgical
bioprosthesis (Figure 1B). Normal function of the surgical aortic valve
prosthesis (mean/peak gradient: 14/27mmHg) as well as normal left
ventricular function (ejection fraction: 60%) were documented.
Multimodality imaging—computed
tomography
Due to the complexity of the disease, cardiac multi-slice computed
tomography (CT) was used for valve sizing, and assessment of the
risk of left ventricular outflow tract (LVOT) obstruction. According
to CT sizing, a bioprosthetic surface of 400.0mm, a 3D annulus per-
imeter of 72.4mm, a projected annulus perimeter of 71.4mm, and an
internal diameter of 22.4mm were measured (Figure 2A). A 26mm
Edwards Sapien 3 valve was simulated for evaluation of the risk of
LVOT obstruction (Figure 2B). LVOT area was 457.6 mm2, whereas
the neo-LVOT area was 385.2 mm2 (Figure 2C) with minimal protru-
sion of the valve into the LVOT. This corresponds to a minimal rela-
tive LVOT reduction of 16%, almost excluding the risk of
obstruction, Furthermore, the aortic–mitral angle was favourable
with a value of 131.8.
Heart team discussion
After completion of the pre-procedural workup, a multidisciplinary
heart team evaluated the therapeutic recommendation. Risk scores
were indicative of high surgical risk [Society of Thoracic Surgery-
Predicted Risk Of Mortality (STS-PROM) score 9.6% and
EuroSCORE II 10.01%], mainly because of pre-operation, previous
stroke, and chronic kidney disease (glomerular filtration rate 36mL/
min). The decision was made to perform a transseptal mitral ViV pro-
cedure combined with the treatment of both PVLs using plug im-
plantation via the same access. Written informed consent was
obtained for the intervention and the publication.
Procedure
The intervention was performed under general anaesthesia and
TOE-guidance. A 8.5-Fr transseptal sheath and needle (BRKTM
Transseptal needle; Abbott/St. Jude Medical) were introduced into
the right femoral vein and advanced over a guiding wire into the right
atrium. Transseptal puncture was performed at the postero-superior
part of the fossa ovalis under TOE-guidance. An AgilisTM NxT
Steerable Introducer (Abbott/St. Jude Medical, St. Paul, MN, USA)
was used to orientate a multipurpose catheter towards the degener-
ated bioprosthesis. Subsequently, the prosthesis was crossed and a
pre-shaped stiff wire (SAFARI2 Guidewire small curve; Boston
Scientific, Marlborough, MA, USA) was positioned in the apex of the
left ventricle using a pigtail catheter. The sheath was exchanged for a
14-Fr eSheath (Edwards Lifescience). Atrial septostomy was per-
formed using a 40 14mm balloon (XXL Balloon Dilatation
Catheter; Boston Scientific). The 26mm Edwards SAPIEN 3 trans-
catheter heart valve was advanced into the degenerated mitral bio-
prosthesis using both fluoroscopy- and TOE-guidance to facilitate
crossing of the septum (Figure 3A). The Sapien 3 valve was then slowly
deployed under rapid pacing (160/min) taking care to align both valve
inflows (Figure 3B). Mean transmitral gradient decreased to 3mmHg.
For PVL closure, a straight guidewire (EMERALDVR Fixed-Core
Guidewire; Cordis, Baar, Switzerland) supported by a 4 Fr straight
.................................................................................................
Day Events
6 years
ago
Combined aortic and mitral surgical valve replacement
4 Hospitalization
3 Assessment of computed tomography and transoeso-
phageal echocardiography
0 Simultaneous transcatheter mitral valve implantation
and percutaneous paravalvular leak closure
1 Intermediate care unit for haemodynamic monitoring
2 Transfer to general ward
5 Discharge without complication
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..catheter (Heartrail II straight; Terumo, Leuven, Belgium) was used to
cross the medial PVL first. After exchange for an 8 French
AmplatzerTM TorqvueTM 45 delivery system (Abbott/St. Jude
Medical, Plymouth, MN, USA), a 10/5mm Amplatzer Vascular Plug III
(AVP III; Abbott/St. Jude Medical, Plymouth, MN, USA) was implanted
reducing PVL to trace (Figure 3C and D). In the same way, a second
AVP III (8/4mm) was positioned into the lateral PVL (Figure 3E and F).
At the end of the intervention overall mitral regurgitation was
reduced to trace (Supplementary material online, Videos S3 and S4).
No post-procedural complication occurs and the patient was dis-
charged after 5 days under oral anticoagulation and acetylsalicylic
acid 100mg/day.
Discussion
Pre-procedural planning
Functional assessment of the valve and PVL localization typically
requires (3D) TOE. The exact differentiation between valvular and
paravalvular regurgitation jets as well as the appreciation of the stabil-
ity of the dehiscent surgical implant are of central importance to de-
termine the treatment strategy. In addition, given the complexity of
the procedure, appropriate planning using CT scan appears crucial. In
our case, CT was used to measure the true diameter of the surgical
valve and assess LVOT. Valve simulation emerges as an important
tool in this setting for preventing the occurrence of LVOT obstruc-
tion during TMVI.5 Indeed, implantation of a valve in mitral position
provokes the displacement of the anterior (in that case
Figure 1 Baseline echocardiographic assessment. (A) Pre-procedural transoesophageal echocardiography 3D atrial view from the surgical mitral
bioprosthesis showing severe stenosis. (B) 3D Doppler atrial view showing the localization of the paravalvular leaks. White arrows indicate the loca-
tion of paravalvular leak.
Figure 2 Pre-procedural computed tomography assessments. (A) Measurements of the bioprosthesis using a short-axis reconstruction. (B) Virtual
valve simulation (26 mm Edwards Sapien 3) in the mitral position (the yellow circle indicates the plane of the aortic bioprosthesis). (C)
Reconstruction and measurement of the anticipated neo-left ventricular outflow tract after mitral valve-in-valve implantation.
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bioprosthetic) valve leaflet that may protrude into the LVOT and
leads to haemodynamic relevant or even life-threatening obstruction.
This risk is more pronounced for valve-in-mitral annular calcification
(MAC) or valve-in-ring interventions and lowest during ViV proce-
dures. Protrusion of the valve into the LVOT creates a smaller neo-
LVOT with a subsequent flow acceleration that is inversely propor-
tional to the smallest cross-sectional area. Additional factors influenc-
ing the size of the neo-LVOT include the aorto–mitral angle, the
length of the anterior leaflet, the presence of a septum bulge as well
as the implantation height.6
Figure 3 Procedure. (A) Positioning of the valve into the degenerated surgical bioprosthesis. (B) Implantation of a 26 mm balloon-expandable
valve. (C) Occlusion the medial paravalvular leak (10/5 mm Amplatzer Vascular Plug III; asterisk). (D) Three-dimensional Doppler atrial view showing
the result after implantation of the first plug and the remaining wide lateral jet. (E) Closure of the lateral paravalvular leak (8/4 mm Amplatzer
Vascular Plug III; second asterisk). (F) Three-dimensional transoesophageal echocardiography view showing the final result after valve-in-valve im-
plantation and implantation of two plugs (asterisks).
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..Transcatheter mitral valve implantation
In a retrospective international registry including 248 patients at 25
centres, TMVI was shown to be a safe and very effective procedure
for patients with a degenerated bioprosthesis in mitral position.2
Procedural complications, in particular, LVOT obstruction or valve
embolization, occurred rarely (3.2 and 1.6%, respectively). However,
patients with valve-in-ring exhibited a higher risk of mortality at
1 year, compared to those with ViV, mainly because of lower proced-
ural success and comorbidities. Differences in access site (transseptal
vs. transapical), did not affect clinical outcomes. A majority of patients
were discharged under oral anticoagulation, while antiplatelet ther-
apy alone appears insufficient in preventing incidental valve
thrombosis.
Percutaneous paravalvular leak closure
Mitral PVL following surgical prosthesis placement is observed in 7–
17% of all cases7,8 and has been linked to a significant risk of heart fail-
ure and haemolysis.9 In the past decade, percutaneous PVL closure
has emerged as an alternative approach due to the high risk of mor-
tality related to redo procedures for surgical PVL closure.10,11
However, it remains a technically challenging procedure in particular
due to the need for precise procedural imaging. Echocardiographic-
fluoroscopic fusion imaging has been proposed to facilitate the navi-
gation in the left atrium and localization of the defect(s).12 In a recent
report including 381 patients who underwent percutaneous or surgi-
cal mitral PVL closure, a higher rate of adverse events occurred in the
surgical group, while no significant difference in long-term (average
follow-up: 85.1± 115.6months) survival was found after adjusting for
comorbidities.13 Successful percutaneous PVL closure, which was
defined as a residual PVL of mild or less, was associated with
improved 1-year survival.14
Combined transcatheter mitral valve
implantation and percutaneous
paravalvular leak closure
Only limited data exist concerning the combination of both proce-
dures. Kliger et al. reported a single-centre case series of TMVI with
concomitant percutaneous PVL closure.4 Five patients with high or
prohibitive surgical risk factors underwent this specific treatment,
using the transseptal or transapical approach. PVL closure was suc-
cessful in all patients with no residual regurgitation using one or two
closure devices. However, in one patient who underwent TMVI using
the Melody valve (Medtronic, Minneapolis, MN, USA) emergent con-
version to open-heart surgery was necessary due to valve emboliza-
tion. The remaining four patients had no complications. One of the
specific challenge of the combined procedure is to avoid interactions
between the different implanted devices to ensure unrestricted func-
tion of the valve leaflets. Appropriate sizing as well as careful intra-
procedural guiding are essential to achieve this goal.
Conclusions
In conclusion, complex mitral valve degeneration affects mainly elder-
ly patients at high surgical risk. In experienced centre, advancements
in interventional and imaging techniques enable safe and effective
percutaneous treatment producing equivalent technical results com-
pared to surgery. Careful pre-procedural planning using multimodal-
ity imaging is essential.
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